Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company ...

Inhibikase Therapeutics (NASDAQ:IKT) has been able to receive a study may proceed letter from the FDA for the use of its drug IKT-001Pro for the treatment of patients with pulmonary arterial ...

Following the completion of the '501' trial, Inhibikase will initiate a discussion with the FDA on the parameters for approval of IkT-001Pro under the 505(b)(2) statute. About IkT-001Pro IkT ...

Inhibikase Therapeutics pivots to focus on IkT-001Pro for pulmonary arterial hypertension after risvodetinib's failure in Parkinson's disease, leveraging imatinib's prior data. The company is well ...

Inhibikase Therapeutics BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical ...

Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing. Get stock ...

After a brief 2.5-month hold, Inhibikase Therapeutics’ Parkinson’s disease therapy is heading back to the clinic. The FDA unexpectedly placed a clinical hold on the midstage therapy IkT-148009 ...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related ...

BOSTON and ATLANTA, Aug. 26, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics ...

Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.